Abstract: Objective To evaluate efficacy and safety of Febuxostat in hyperuricemic patients compared with Allopurinol by systematic review. Methods Electronic databases （PubMed,the Cochrane library,EMBASE,CNKI,Wanfang,CBM,ect） were searched for articles of all publication years（up to February 2017）. According to the inclusion and exclusion criteria,tow reviewers independently selected articles,extracted data and evaluated quality. Randomized controlled trials（RCTs） were analyzed by meta-analysis. Results 23 RCTs were included. A significantly greater proportion of patients achieved the target serum urate level （sUA<6.0 mg/dL） at the final visit in the Febuxostat groups （40 mg/d: RR1.14,95%CI 1.05~1.23,P=0.001; 80 mg/d: RR 1.72,95%CI 1.61~1.83,P<0.000 01; 120 mg/d: RR 2.04,95%CI 1.85~2.26,P<0.000 01） compared with the Allopurinol groups. Conclusion Compared with Allopurinol（100~300 mg/d）,Febuxostat（80~240 mg/d） showed more effective outcome and may reduce the incidence of rash.